ALY688ER is a sustained release systemic formulation of ALY688 formulated for SC administration. In fibrosis-associated animal models such as Duchenne muscular dystrophy, liver fibrosis, cardiac remodeling, and lung fibrosis, ALY688 is potent inhibitor of tissue-related inflammation and fibrosis. Because of its broad actions against underlying disease pathways involving excessive inflammation and fibrosis, it offers potential as a Pipeline-in-a-Product opportunity, where it may have therapeutic benefit across multiple common and rare diseases.

 

ALY688 Ophthalmic Solution is an ophthalmic formulation of ALY688 for eye drop administration. In relevant animal models, ALY688 accelerated epithelial (corneal) healing following injury due to alkali burn and corneal epithelial scraping. It is being developed as a medical countermeasure to reduce damage following ocular exposure to toxic agents including vesicants such as sulfur mustard gas. 

​

​

​

​

​